Electric Tumor Treatment Field Therapy
Policy governing medical necessity coverage criteria, continuation criteria, definitions, applicable codes, and evidence summary for use of FDA‑approved electric tumor treatment field (TTF) devices (e.g., Optune) for supratentorial glioblastoma (newly diagnosed and recurrent) and discussion of other tumor sites (not covered/evidence insufficient).
Removed language indicating computer software used for therapeutic radiology clinical treatment planning in conjunction with electric tumor treatment fields (TTF) therapy is unproven and not medically necessary.
Updated Medical Records Documentation Used for Review; added requirements for physician notes for newly diagnosed and recurrent glioblastoma.
Removed CPT code 77299 from Applicable Codes.
Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect current information.